<DOC>
	<DOCNO>NCT02359877</DOCNO>
	<brief_summary>This international multicenter study tolerability , pharmacokinetics pharmacodynamics drug product BCD-054 ( CJSC BIOCAD , Russia ) , administrate intramuscular subcutaneous , compare Rebif® ( Merck Serono S.p.A. , Italy ) Avonex® ( Biogen Idec Ltd , UK ) healthy volunteer . The study involve 2 stage - single ascend dose administration multiple estimate therapeutic dose administration BCD-054 .</brief_summary>
	<brief_title>Open Label Study Tolerability , Pharmacokinetics Pharmacodynamics BCD-054 ( Pegylated Interferon Beta-1a ) , IM SC , Compared Rebif® Avonex® Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>In 1 . Written informed consent ; 2 . Male gender ; 3 . Age 18 45 year inclusive ; 4 . Body mass index ( BMI ) ( 18,5 24,99 kg/m2 ) ; 5 . Healthy condition proven volunteer 's history , global assessment laboratory analysis result : Absence past medical history screen clinically significant dysfunction circulatory , respiratory , nervous , hematopoietic , endocrine digestive system , liver kidney ; No history cardiovascular diseases diseases thyroid gland Haematology biochemistry test , urinalysis thyroid hormone analysis result within normal limit accord standard study site . Screening laboratory analysis perform 14 day volunteer 's inclusion study ; Hemodynamic parameter within normal limit : systolic blood pressure 100 139 mmHg , diastolic blood pressure 60 90 mmHg , heart rate 50 90 bpm ; Absence history chronic infection ( tuberculosis ) chronic inflammation ; Absence HIV , hepatitis B C virus , syphilis ; Absence acute infection within 4 week inclusion study ; Absence psychiatric disorder condition interfere volunteer 's ability follow study protocol , include depression ; Wellbeing ( volunteer 's opinion ) within 30 day participation study ; 6 . Absence history systematic alcohol drug abuse ; 7 . Ability volunteer , investigator 's opinion , follow study protocol procedures requirement ; 8 . Willingness volunteer sexual partner childbearing potential use reliable contraception method start 2 week inclusion study 4 week receive last dose investigational product . This criterion applicable patient underwent surgical sterilization . Reliable contraceptive measure include one barrier method combination one follow method : spermicide , intrauterine device oral contraceptive use participant 's partner ; 9 . Consent avoid alcohol intake within 24 hour 8 day administration test reference drug ; 10 . Consent avoid grapefruit juice ( product contain grapefruit ) intake within 72 hour 8 day administration study reference drug . 1 . Previous use IFNβ1containing medication time inclusion ; 2 . History serious allergic reaction ( anaphylaxis multiple allergy ) ; 3 . Known allergy intolerance interferon component study reference drug pegylated protein ; 4 . Major surgery within 30 day screen ; 5 . Impossibility install venous catheter blood sampling ( e.g . skin disorder sit venipuncture ) ; 6 . Diseases condition interfere investigational drug pharmacokinetics ( e.g . chronic liver , kidney , blood , circulatory system , lung neuroendocrine disease , include diabetes mellitus others ) ; 7 . History fever 40°С 8 . History increase aminotransferase ( ALT , AST ) &gt; 2.5 × ULN 9 . History epileptic seizure ; 10 . Depression and/or suicidal idea , suicide attempt history 11 . Regular oral parenteral use medication include overthecounter drug , vitamin nutritional additive within less 2 week inclusion study ; 12 . Intake medication , include overthecounter drug biologically active additive influence hemodynamics , liver function etc . ( barbiturate , omeprazole , cimetidine etc . ) within less 30 day inclusion study ; 13 . Intake medication influence immune status ( cytokine inductor , glucocorticoid etc . ) within less 30 day inclusion study ; 14 . Vaccination within 4 week prior inclusion 15 . Smoking 10 cigarette per day ; 16 . Subjects consume 10 unit alcohol per week history alcohol abuse evidence drug/chemical abuse ( one unit alcohol equal ½ l [ 500 ml ] beer , one glass [ 200 ml ] wine l shot glass [ 50 ml ] spirit ) ; 17 . Donation 450 ml blood plasma within 2 month inclusion study ; 18 . Participation clinical study within less 1 month inclusion study simultaneous participation another clinical study ; 19 . Previous participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>pegylated interferon beta</keyword>
	<keyword>Volunteers</keyword>
</DOC>